| Molecular Feature | Details/Findings | Relevant Gene/Pathway | Significance | Key Reference |
|---|---|---|---|---|
| Germline BMP15 missense mutation in hereditary ovarian teratoma | A rare BMP15 C262T missense variant was identified in two pedigrees with hereditary ovarian immature teratoma; the mutation reduces mature BMP15 secretion by ~84.7% and supports an X-linked dominant hereditary form affecting heterozygous females. | **BMP15**; oocyte growth factor signaling | Strongest recent human genetic evidence for a causal predisposition gene in hereditary ovarian teratoma; supports molecular diagnosis and genetic counseling in high-risk families. | PNAS 2024 BMP15 study (pqac-00000022, pqac-00000026, pqac-00000027) |
| Parthenogenetic origin of ovarian teratomas | Mature ovarian teratomas are described as parthenogenetic tumors containing only maternal genomes; they are thought to arise from a single ovarian germ cell/oocyte after meiotic errors or spontaneous activation without fertilization. | Oocyte meiosis / parthenogenesis | Explains why many ovarian teratomas show near-diploid genomes with limited somatic mutation burden and distinctive imprinting features. | Diagnostics 2023; Cancers 2023; PNAS 2024 (pqac-00000008, pqac-00000010, pqac-00000027) |
| H-Ras/MAPK pathway activation | In BMP15-mutant oocytes, spontaneous parthenogenetic activation increased markedly, accompanied by elevated **H-Ras** and **MEK1** expression and MAPK pathway activation. | **H-Ras**, **MEK1**, **MAPK signaling** | Provides a mechanistic link between the BMP15 variant and abnormal oocyte activation leading to teratoma formation. | PNAS 2024 BMP15 study (pqac-00000023, pqac-00000025, pqac-00000026) |
| GDF9/BMP15 signaling imbalance | The BMP15 variant may alter the balance between BMP15 homodimers/heterodimers and **GDF9**-related signaling, shifting downstream signaling outputs and enhancing pathways that favor parthenogenesis. | **BMP15**, **GDF9**, **BMPR2**, SMAD/MAPK-related signaling | Suggests that altered oocyte–granulosa cell signaling balance is an upstream event in hereditary teratoma pathogenesis. | PNAS 2024 BMP15 study (pqac-00000023, pqac-00000025, pqac-00000029) |
| DNA methylation subtype differences | Ovarian germ cell tumors show subtype-specific methylation states: undifferentiated germinomas are relatively hypomethylated, whereas differentiated tumors including mature teratomas are more hypermethylated. | DNA methylation / epigenetic regulation | Supports the idea that differentiation state and cell of origin are reflected in methylation profiles; potentially useful for tumor classification and pathogenesis studies. | Cancers 2023 review (pqac-00000011, pqac-00000012, pqac-00000013) |
| Epigenetic imprinting abnormalities | Ovarian teratomas show abnormal imprinting patterns, including reduced methylation at paternally methylated loci and increased methylation at maternally methylated loci; IGF2/H19 imprinting abnormalities have also been reported in ovarian GCTs. | Genomic imprinting; **IGF2/H19** control region | Reinforces the maternal-genome/parthenogenetic model and indicates that imprint erasure/re-establishment defects are central to teratoma biology. | Cancers 2023 review (pqac-00000011, pqac-00000013, pqac-00000014) |
| Chromosomal abnormality: isochromosome 12p / 12p gain | Gain of chromosome 12p, including **isochromosome 12p**, is frequent in malignant germ cell tumors, especially dysgerminomas and yolk-sac tumors, but is less characteristic of immature teratomas and generally absent from mature teratomas with normal karyotype. | **12p gain / i(12p)** | Helps distinguish malignant ovarian GCT molecular pathways from the more parthenogenetic, usually cytogenetically bland pathway of mature teratoma/dermoid cyst. | Cancers 2023 review; IJERPH 2023 review (pqac-00000009, pqac-00000010) |
| Near-diploid genomes with limited somatic mutations | Immature teratomas may show near-diploid genomes, extensive allelic imbalance, and relative paucity of somatic mutations; mature teratomas often have normal karyotypes and arise after meiosis. | Meiotic nondisjunction; allelic imbalance | Indicates that abnormal germ-cell developmental/meiotic processes, rather than classic oncogenic mutation accumulation, drive teratoma formation. | Diagnostics 2023; Cancers 2023 (pqac-00000008, pqac-00000010, pqac-00000014) |
| Distinct pathogenetic pathway of immature teratoma | Immature teratomas appear to follow a pathogenetic route distinct from dysgerminoma/yolk-sac tumor and from some mature teratomas, with less emphasis on 12p gain and more on meiotic errors and epigenetic dysregulation. | Developmental germ-cell pathways | Important for biological classification, prognosis, and future risk stratification/targeted research. | Diagnostics 2023; IJERPH 2023; Cancers 2023 (pqac-00000008, pqac-00000009, pqac-00000010) |


*Table: This table summarizes the main molecular and genetic findings relevant to ovarian dermoid cysts/teratomas, emphasizing recent evidence on BMP15-associated hereditary teratoma and broader germ-cell tumor epigenetics and cytogenetics. It is useful for distinguishing developmental/parthenogenetic mechanisms from malignant germ-cell tumor pathways.*